Septerna (NASDAQ:SEPN) Rating Increased to Hold at Zacks Research

Septerna (NASDAQ:SEPN) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other equities research analysts also recently issued reports on SEPN. Wall Street Zen downgraded shares of Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. HC Wainwright lifted their target price on Septerna from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Wells Fargo & Company upgraded Septerna from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $18.00 to $28.00 in a research note on Friday, November 14th. Finally, Raymond James Financial initiated coverage on Septerna in a research report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.83.

Septerna Stock Down 2.8%

SEPN opened at $29.99 on Tuesday. The firm’s 50 day moving average is $26.90 and its 200-day moving average is $22.09. Septerna has a 52-week low of $4.66 and a 52-week high of $32.63. The firm has a market capitalization of $1.34 billion, a P/E ratio of -19.86 and a beta of 3.85.

Insiders Place Their Bets

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at $5,046,834.73. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Septerna

Institutional investors have recently made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Septerna by 116.7% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock worth $2,354,000 after purchasing an additional 119,953 shares during the period. Group One Trading LLC boosted its holdings in shares of Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares during the period. Global Retirement Partners LLC bought a new stake in shares of Septerna during the 4th quarter valued at about $35,000. Baader Bank Aktiengesellschaft acquired a new stake in Septerna during the fourth quarter worth about $279,000. Finally, Strs Ohio bought a new position in Septerna in the fourth quarter worth about $407,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.